Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions.
Autor: | Wang SV; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA. swang1@bwh.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. swang1@bwh.harvard.edu., Sreedhara SK; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA., Schneeweiss S; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA. |
---|---|
Jazyk: | angličtina |
Zdroj: | Nature communications [Nat Commun] 2022 Aug 31; Vol. 13 (1), pp. 5126. Date of Electronic Publication: 2022 Aug 31. |
DOI: | 10.1038/s41467-022-32310-3 |
Abstrakt: | Studies that generate real-world evidence on the effects of medical products through analysis of digital data collected in clinical practice provide key insights for regulators, payers, and other healthcare decision-makers. Ensuring reproducibility of such findings is fundamental to effective evidence-based decision-making. We reproduce results for 150 studies published in peer-reviewed journals using the same healthcare databases as original investigators and evaluate the completeness of reporting for 250. Original and reproduction effect sizes were positively correlated (Pearson's correlation = 0.85), a strong relationship with some room for improvement. The median and interquartile range for the relative magnitude of effect (e.g., hazard ratio (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |